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Despite	 the	 great	 effort	 to	 decrease	 the	 HIV	 infectivity	 rate,	 current	 antiretroviral	 therapy	 has	
several	weaknesses;	poor	bioavailability,	development	of	drug	resistance	and	poor	ability	to	access	
tissues.	 However,	 molecules	 such	 as	 peptides	 have	 been	 regarded	 as	 a	 new	 strategy	 for	 HIV	
eradication.	The	vaginal	mucosa	is	the	main	spreading	point	of	HIV.	There	are	natural	barriers	such	
as	the	vaginal	fluid,	which	protects	the	vaginal	epithelium	from	foreign	agents.	Here	we	developed	




inhibitor	 peptide	 (E2).	 	 In	 vitro	 release	 and	 ex	 vivo	 studies	 were	 carried	 out	 using	 the	 vaginal	
mucosa	 of	 swine,	 and	 the	 peptide	was	 determined	 by	 HPLC	MS/MS.	Moreover,	 the	 peptide	was	
labelled	with	5(6)-carboxyfluorescein	and	entrapped	in	the	NPs	for	studies	 in	vivo	to	examine	the	
penetration	 and	 toxicity	 of	 the	NPs	 in	 the	 vaginal	mucosa	 of	 swine.	 The	mean	 size	 of	 the	NPs,	 Z	
potential	 and	 the	 loading	 percentage	 were	 critical	 to	 determining	 whether	 the	 NPs	 reach	 the	
vaginal	 tissue	 and	 release	 the	 peptide	 within	 intercellular	 space.	 	 The	 results	 indicate	 that	 the	
fusion	inhibitor	peptides	loaded	into	the	NPs	coated	with	GC	might	lead	to	the	development	of	new	

















The GB virus C (GBV-C) is a non-pathogenic member of Flaviviridae family; it is a lymphotropic virus 
that replicates in human peripheral blood mononuclear cells (PBMC), including B and T lymphocytes.  
[1]. Several studies show that: (a) GBV-C infection is associated with slower progression and prolonged 
survival in HIV-infected patients. (b) When GBV-C is added to CD4+ T cells it inhibits HIV entry. (c) 
Transmission of HIV-1 from mother to child is reduced in mothers co-infected with GBV-C [2]. (d) The 
RNA+ of GBV-C in HIV patients correlates with lower activation of T lymphocytes [3]. These findings 
have been used to develop new strategies against the spread of HIV.  
	
Two GBV-C viral proteins, NS5A and E2, inhibit HIV replication in vitro. NS5A induces the expression 




CD4+ T cells to HIV infection [4]. The E2 envelope glycoprotein appears to inhibit the earlier steps of 
HIV infection, due to an internal fusion peptide that inhibits gp41 fusion to the cell targets [5]. The use of 
small peptides derived from GBV-C envelope proteins has thus been suggested as a strategy to inhibit 
HIV-infection [6–8]. 
In an attempt to decrease the rate of HIV infection, a broad range of HIV-1 fusion-entry inhibitors have 
been explored. Several HIV inhibitors have been reported to block the entry of HIV to target-cells. For 
example, VIRIP, a derivate from serine protease inhibitor (α-1antitrypsine) inhibits HIV-1 entry by 
binding to the fusogenic peptide in gp41 (gp41-FP) and preventing its insertion into the target-cell [9]. 
Enfuvirtide (T-20), a peptide derived from gp41, blocks conformational changes in gp41 and thus inhibits 
HIV-1 fusion to cells [10].  E2, a peptide derived from the E2 envelope protein of GBV-C, interacts with 
the disulphide loop region in gp41of HIV. E2 contains three cysteine residues, which may interfere with 
the oxidation state of the cysteine in the gp41 disulphide region. [11,12].  
Unfortunately, peptides suffer from limitations such as:  low oral bioavailability, short half-life, fast 
removal and poor ability to cross-physiological barriers. Moreover, hydrophobicity and flexibility can 
reduce specificity and trigger activation of different receptors or targets, leading to side effects [13].  
HIV is mainly transmitted through infected vaginal and rectal mucosae. Research on the prevention of 
HIV infection has focused on the development of topical microbicides. However, the first-generation HIV 
microbicides failed as a result of genital epithelial disruption and inflammation [14]. Damage to the 
epithelial lining as a result of physical and chemical stress can increase the incidence of HIV, and 
facilitate penetration of submucosal tissue. Further, the microbiota change in the vaginal mucosa, 
following prolonged exposure to the high doses of drugs, could lead to a breakdown of the defense barrier 
in the mucosa and therefore facilitate HIV infection [15].  
The vaginal fluid that covers the mucosa can help the microbicide to reach the epithelium, or remove the 
microbicide. Unless vaginal microbicides satisfy essential criteria of stability, safety, effectiveness and 
tolerability, their efficacy and toxicity might be compromised during permeation across mucosal tissue 
[16].	
A new generation of HIV microbicides is being manufactured with biodegradable carriers such as 
liposomes, nanoparticles, dendrimers, gels, and films, in order to improves the safety and effectiveness of 
the drugs [16–18]. The systems most widely used for this purpose are nanoparticles made with 
polyesthers such as poly (D, L-lactic-co-glycolic acid) (PLGA). This polymer has been approved by Food 
and Drug Administration (FDA) and used as colloidal carriers for drug controlled release [19].  It has 
several advantages such as biocompatibility, biodegradability and non-toxicity [20]. In addition, PLGA 
shows good reproducibility, controllable release and predictable degradation kinetics [21]. In addition, 
PLGA properties such as bioadherence and mucoadhesiveness are comparable to the mucoadhesive 
properties of biopolyaminossacharides such as chitosan. Chitosan, a deacylated product of the linear 





Polymeric nanoparticles (NPs) have been considered as a suitable carrier to entrap proteins and 
polypeptides, since NPs target specific localization, which offers controllable and site-specific peptide 
release. In addition, NPs as carriers of anti-HIV peptides have the specific potential to address the main 
issues of traditional HIV-1 therapy, such as overcoming cellular and anatomical barriers, drug toxicity, 
drug resistance, suboptimal adherence and virus sequestration [25]. For example, NPs have been used 
extensively to entrap therapeutic peptides and to improve their activity. In this sense, an analogue of 
RANTES (PSC-RANTES) encapsulated in polymeric NPs maintained comparable anti-HIV activity with 
unformulated PSC-RANTES in HeLa cells. Studies ex vivo demonstrated that PSC-RANTES carried by 
NPs increased tissue uptake and enhanced both tissue permeation and leading localization at the basal 
layers of the epithelium compared with unformulated PSC-RANTES [26] . 
Here we developed PLGA Nanoparticles (NPs) covered with glycol-chitosan to encapsulate an HIV 
fusion inhibitor peptide (E2). Furthermore, we carried out assessments ex vivo and in vivo to examine the 
ability of NPs to reach the vaginal epithelium. The penetration rate was measured in a swine model using 
confocal microscopy.	
2. Materials and methods	
2.1. Materials 	
Fmoc-protected amino acids, NovaSyn TGA, TGR resins as well as 5(6)-carboxyfluorescein 5(6)-FAM) 
were purchased from Novabiochem (Merck Millipore, Merck KGaA, Darmstad, Germany). Peptide-
synthesis-grade dimethylformamide (DMF) and trifluroacetic acid (TFA) were obtained from Scharlau 
(Barcelona, Spain). Diethyl ether, dichloromethane (DCM) and methanol were obtained from Merck 
(KGaA, Darmstad, Germany). 2-(1H-7-azabenzotriazole-1-yl)-1.1.3.3-tetramethyluronium 
hexafluorophosphate methanaminium (HATU) was from Genscript (Piscataway, NJ, USA). 
Diisopropylethylamine (DIPEA), piperidine, triisopropylsilane, N’, N’-diisopropylcarbodiimide 
(DIPCDI), 1-hydroxybenzotriazole (HOBt), trimethylamine, Glycol Chitosan, 4-(2-Hydroxyethyl) 
piperazine-1-ethanesulfonic acid (HEPES); 1,4 dithiothreitol (DTT), Paraformaldehyde (PFA) were 
purchased from Fluka Sigma-Aldrich (St. Louis, MO, USA). PLGA 50:50 monomer ratio (RG 503H, mw 
34 kDa, [η] = 0.32–0.44 was purchased from Boehringer Ingelheim (Ingelheim, Germany). Polyvinyl 
alcohol (PVA) was obtained from BASF (Barcelona, Spain). Potassium dihydrogen phosphate, disodium 
hydrogen phosphate, acetic acid was from Panreac (AppliChem GmbH, Darmstadt, Germany) HPLC-
grade acetonitrile (ACN) was purchased from Fisher Scientific (Loughborough, UK). Double-distilled 
water was obtained from a Milli-Q® Gradient A10 system apparatus (Millipore Iberia S: A: U; Madrid, 
Spain). Tissue-Tek® O.C.T. Compound was purchase from Sakura Finetek, USA. 1,5-bis {[2-(di-
methylamine) ethyl] amino}-4,8-dihydroxyanthracene-9,10-dione (DRAQ5), were purchase from BD 










2.2.1 Synthesis of peptides	
E2 peptide was synthetized by solid-phase peptide synthesis (SPPS) and Fmoc/tBut. A NovaSyn TGA 
resin functionalized with hydroxymethylphenoxyacetic acid (HMPA) was acetylated with the 
symmetrical anhydride of the C-terminal amino acid (Fmoc-GLy-OH) as described by Gomara et al., 
[27]. Couplings were performed by HATU/DIPEA activation with three-fold molar excess of Fmoc-
amino acids. The Fmoc was deprotected twice with (20%) piperidine in DMF for 10 minutes. The 
stepwise addition of each residue was assessed by Kaiser’s test and by the chloranil test for identification 
of secondary amines (proline residues).	
Before the cleavage, the E2 peptidyl-resin was labelled at the N-terminus with 5(6)-carboxyfluorescein, 
5(6)-FAM). The carboxylic acid group of the fluorescent dye was activated with N, N’-
diisopropylcarbodiimide (DIPCDI) and hydroxybenzotriazole (HOBt). Coupling was carried out with 
three-fold molar excess of the reagents. Fluorescent labeling of the E2 peptidyl-resin was evaluated by 
Kaiser’s test.	
The peptide was side chain deprotected and cleaved from resins by a treatment of trifluoroacetic acid 
TFA, triisopropylsilane (TIS) and water: 9.5%, 2.5%, and 2.5. The reaction was carried out for 3 hours at 
room temperature. The solvents were evaporated in vacuum and the crude peptide was precipitated with 
cold diethyl ether. Precipitated peptide was dissolved in 30% glacial acetic acid in water and lyophilized.	
The peptide was purified by semi preparative HPLC (1260 Infinity, Agilent Technologies, Santa Clara, 
CA, USA) in an XBridgeTM Prep C8 column (5 µm, 10x 250 mm, Waters, Milford, MA, USA. E2 was 
analyzed using a Waters Alliance HPLC with diode array detector with analytical column Kromasyl 100 
C18 column (250mm × 4.6mm, 5µm, Teknokroma). The analyses were carried out with linear gradient of 
95% water (0.05% TFA) / 5% acetonitrile (0.05% TFA). The peptide was purified at 95% by analytical 
HPLC at 220 nm. E2 and E2-FAM were examined by electrospray ionization mass spectrometry (ESI-
MS). The methods are reported in detail in supplementary materials section.	
	
2.2.2. Preparation of the PLGA NPs loaded with E2-FAM (NPsE2-FAM) 	
The NPs were manufactured by a modified double emulsion method [28]. NPs with E2, E2-FAM and 
empty NPs were prepared individually. In brief, the NPs were prepared with 50 mg of PLGA dissolved in 
1 mL of dichloromethane (organic phase).  The preparation was then emulsified under sonication (30 s, 
50 W) with a solution containing 1.5 mg of either E2 or E2-FAM, forming a water-in-oil-water emulsion 
(W1/O/W2). Afterwards, the first emulsion (W1/O) was added to 6 mL of previously prepared solution 
(2.5 % PVA and chitosan 0.05%, at pH 4.0) and the mixture was emulsified again by sonication (1 
minute, 50W), forming a double emulsion (W1/O/W2). The emulsion was stirred overnight to evaporate 
the solvent and to form and harden the NPs. 	
NPs were purified by ultracentrifugation for 15 minutes, 15000 rpm; at 4ºC (Beckman Coulter, OPTIMA 





2.2.3. Physicochemical Characterization of the NPsE2 	
The average particle size (Zav) and polydispersity index (PI) of both NPsE2-FAM and NPsE2 were 
determined by photon correlation spectroscopy (PCS) (after 1:10 dilution) with a Zetasizer Nano ZS 
(Malvern Instruments, Malvern, UK) at 25 ºC using disposable quartz cells and (Malvern Instruments). 	
NP surface charge, measured as Z Potential (ζ), was evaluated using laser-Doppler electrophoresis with 
M3 PALS system in ZetasizerNano ZS. ζ indirectly indicates the rate of aggregation of particles. A 
greater ζ (in absolute value) would induce less aggregation due to repulsion forces between the particles. 
The ZP was calculated applying the Henry equation [29]. 	
	
𝜇! =  
!"#(!")
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               (1)	
	
 where 𝜇!  is the electrophoretic mobility, 𝜀 is the dielectric constant of the medium, ζ is the zeta 
potential, η is the medium viscosity, 𝐾𝑎 is the Deybye-Hückel parameter and 𝑓 (𝐾𝑎) is a correction 
factor that considers the thickness of the electrical double layer (1/𝐾) and particle diameter represented by 
(a). The unit of 𝐾 is a reciprocal length. The reported values correspond to the mean ± SD of at least three 
different batches of each formulation 	
	
2.2 4. Entrapment efficiency (EE %)	
The EE percentage of the peptide loaded into the NPs was calculated indirectly by measuring the 
concentration of the peptide in the dispersion medium. The non-entrapped E2 was separated from the 
entrapped E2 by ultracentrifugation (at 15000 rpm for 15 minutes, 4ºC). The concentration of the non-
entrapped peptide was measured by HPLC UV-VIS. The HPLC system was connected to a Waters® 515 
HPLC Pump (Waters, Milford, MA, USA). The analytical column was a Kromasil 100 C18 
(250mm×4.6mm, 5µm, Teknokroma). The peptide was detected at 280 nm with a flow rate of 1.0 ml/min. 
The eluents were 95% water (0.05% TFA) and 5% acetonitrile (0.05% TFA) (95:5 v/v). Each sample was 
diluted with acetonitrile/ water (1:10). The EE (%) was determined applying Eq (2). 
𝛦𝛦 (%) = !"#$% !"#$%& !"  !"!#$%" – !"## !"!#$%"
!"#$% !"#$%& !" !"!#$%"
· 100      (2) 
2.2.5. Amino acid analysis 
The amino acids composing the peptide entrapped in the NPs were identified and quantified as described 
by Cohen et al.,[30,31]. In brief, 30 µL of 1- amino-n-butyric acid (2.5 mM) and 1 mL of HCL 12 M 
were added to 1 mL of the sample (NPsE2 suspension, 166 µg/mL of E2 peptide). Hydrolysis was carried 
out at 110 ºC for 16 hours. The internal standard (10 mL) was added and diluted with water to 250 mL. 
The solution was passed through a 0.20 µm filter. Then, the acid was evaporated and dried sample was 
dissolved with Milli-Q water.  
 




standard. The optimal pH range for derivatization is 8.2–9.7, and the solution was briefly vortexed. Then, 
20 µL of reconstituted AccQ.Fluor reagent (3 mg/ml in acetonitrile) was added and the mixture was 
immediately vortexed. The vial was closed and left to stand for one minute at room temperature. It was 
then placed in a heating block at 50 °C, for 10 minutes.  
 
Chromatographic separation was carried out in a Waters	AccQ.Tag amino acid analysis Nova-PakTM 
column (3.9 mm × 150 mm, 4 µm) fitted with a Nova-PakTM C 18. The column was thermostatted at 37 
ºC and a flow rate of 1.0 mL/min. The injection volume was 20 µL. Mobile phase A consisted of 
AccQ.Tag eluent A, (100 mL AccQ.Tag A concentrate + 1 L Milli-Q water). Mobile phases B and C 
were acetonitrile and Milli-Q  water, respectively. Reaction of amino acids with 6-aminoquinolyl-N-
hydroxysuccinimidyl carbamate yielded derivatives that were detected at 254 nm. Qualitative and 
quantitative analyses were based on retention times and internal standard method, respectively.  
 
2.2.6 Release studies in vitro 	
The evaluation of the peptide released from NPsE2 were carried out in amber glass Franz type diffusion 
cells (FDC-400) of 18 mm diameter. A dialysis cellulose membrane MW 12000-14000 Da (Iberoamerica, 
Spain) was hydrated with the receptor medium (pH 7.4 phosphate buffer 10 mM, DTT 10 mM) for 24 
hours before use. The membrane was fastened between the donor and the receptor compartments of Franz 
cells. The donor compartment was filled with 1 mL of NPsE2. The receptor compartment was filled with 
5 mL of the receptor medium. The available diffusion area was 0.62 cm2. The temperature of the 
assessment was controlled at 37 ± 1ºC to mimic human body temperature. The sink conditions were 
sustained throughout the experiment for 10 hours. Aliquots of 100 µL were withdrawn from the receptor 
chamber at fixed time intervals and immediately replaced with an equal volume of fresh buffer. The 
quantification of E2 released was analyzed by HPLC-MS/MS, using a validated method. The 
concentration of E2 released was measured as described previously for EE. The data are reported as the 
mean ± SD of three replicates.	
The amount of E2 released was adjusted to the Boltzmann Sigmoidal kinetic model (Samaha et al., 
2009)[32] . 	
  𝑚 = !!!!!
!!!(!!!!)/!
+ 𝛢!       (4)
         
where (m) is the mass of each sample expressed in ng. (A1) is the low Y limit, (A2) is the high Y limit, (k) 
is the slope and (t0) represent the V50. V50 is a modelistic parameter that can determine the time in which 





professional edition version 3.3 and Graphpad prism version 6 
Demo).	
The methods used to detect and quantify E2 (HPLC MS/MS and HPLC UV-VIS), were validated 
following the ICH guidelines [33]. The HPLC UV-VIS method was validated using acetonitrile/water as 




studied were: linearity, by determination of slope, intercept, 95% confidence intervals and the regression 
coefficient (r), limit of detection (LOD) and limit of quantification (LOQ). The precision inter-day was 
expressed as the mean of the coefficient of variation (CV). Accuracy was defined as the mean of the 
percentage deviation (EE) for the HPLC UV-VIS method, whilst the accuracy by HPLC MS/MS, was 
defined as the mean of recovery percentage (RE).  
The validation parameters of HPLC UV-VIS and HPLC MS/MS are shown in Tables 2 and 5 
respectively. The methods are reported in detail in supplementary materials section. 
	
2.2.7. Penetration of the NPsE2 in vaginal mucosa of swine	
The penetration was evaluated using NPsE2 and NPsE2-FAM. NPs were carried out for both assessments 
ex vivo and in vivo. For assessments ex vivo, the vaginal mucosae were obtained from the animal house at 
Bellvitge (Barcelona University); according to protocol approved by Ethics Committee at the University 
of Barcelona. The mucosae were maintained in a cryoprotective solution and stored at -80 ºC until use, 
following the protocol described by Amores et al [34].  
	
2.2.7.1. Evaluation ex vivo of the penetration rate of the NPsE2-FAM and the retained amount of E2 	
Both the penetration rate and the amount retained were measured using 5 mL Franz cells. The donor 
compartment contained either NPsE2 or NPsE2-FAM (n=3), and the receptor compartment was filled 
with the mix of receptor medium and Transcutol P® 50:50 (v/v), so as to ensure a high solubility of E2. 
Diffusion testing was performed at 300 rpm and 37 ± 1 ºC. The full thickness mucosa discs were placed 
between the two cell compartments. The available diffusion area was 0.62 cm2. A clamp was used to hold 
the compartments together. Each assay was performed by triplicate.	
To evaluate the penetration rate, at the end of the experiment (5 hours), the vaginal tissues were removed 
and fixed in paraformaldehyde 4% (PFA) for 24 hours. Subsequently, the tissues were immersed in 
sucrose 30% and embedded in the Tissue-Tek® O.C.T. compound, immersed in liquid nitrogen and stored 
at -80ºC. 25 µm sections perpendicular to the mucosal surface were cut on a cryostat (Leica CM1510, 
Leica Microsystems) at -20 ºC. 	
The cell nuclei of the tissues were stained with a solution of DRAQ5 (1:2000). The slides were observed 
using a confocal laser-scanning microscope (TCS-SL-Leica Microsystems) using λexc: 488 nm for the 
visualization of the NPsE2-FAM. The acquired images were processed by the means of IMAGE-J 
software.	
To determine the retained E2 amount, at 5 hours intervals, aliquots of 300 µL were withdrawn from the 
receptor chamber and immediately replaced with an equal volume of receptor medium. At the end of the 
experiment, tissues were removed and rinsed in PBS and the permeation areas were cut and weighed. The 
E2 retained in the mucosa was extracted with a mixture of the receptor medium and acetonitrile (80:20, 
v/v); the solution and the mucosa were mixed for 20 minutes under cold sonication in an ultrasound bath. 






2.2.7.2. Evaluation in vivo of the penetration rate of NPsE2-FAM 	
Experiments were conducted using four female swine of 25 kg. Before carrying out the experiments, the 
animals were anesthetized. Aliquots of 1 mL of NPsE2-FAM (0.3 mg/mL) were poured, into the vaginal 
area. Afterwards, the animals were sacrificed by anesthesia overdose and intact vaginal mucosa was 
isolated using surgical scissors. Tissues slices were used to evaluate both the NP toxicity and the NPsE2-
FAM penetration.	
The penetration of NPsE2-FAM was analyzed using a confocal microscope. After the exposure (2 and 5 
hours), the tissues were fixed by dipping them into PFA (4%) over-night, immersed in sucrose 30% for 5 
hours, embedded in Tissue-Tek® O.C.T. compound and immersed in liquid nitrogen. 20 µm sections 
perpendicular to the mucosa surface were cut on a cryostat (Leica CM1510, Leica Microsystems) at -20 
ºC. The nuclei were stained with DRAQ5. The slides were observed on a confocal laser-scanning 
microscope, using λexc: 488 nm for the visualization of NPsE2-FAM. The acquired images were 
processed by IMAGE-J software. 	
To evaluate the toxicity of NpsE2-FAM, water was applied to one untreated animal. This was to verify 
the normal tissue architecture and inflammation status in the vaginal mucosa, following the process 
mentioned above. Tissues were paraformaldehyde fixed, embedded in paraffin and stained with 
hematoxylin and eosin. Tissue slices were visually examined for histological features, in a blinded 
method, using a transmitted-light microscope (Epi-fluorescence microscopy, NIKON). The 
morphological condition of the vaginal mucosa was examined in 10 different slides.	
	
 2.8. Statistical analyses	
Multiple comparisons were obtained by one-way ANOVA with either Turkey’s or a run test, except the 
histological and confocal studies, which were acquired by using a specific program (Image J). Data are 
presented as a mean ± SD	
3. Results and discussion 	
3.1. Peptide synthesis 
	
E2 is a 20- mer peptide [LCDCPNGPWVWVPAFCQAVG], with a MW of 2165, characterized by its 
high hydrophobic content and the presence of three cysteine residues [11]. These properties enable it to 
interact with the sequence in the disulphide-loop region in gp41 and to block HIV-1 fusion to the cells. 
Their specificity and activity was confirmed by comparison with a peptide in which the amino acids were 
arranged randomly (random peptide). The random peptide showed significantly higher IC50 values against 
two different HIV strains than the parent sequence. These findings confirmed that E2 may interfere with 
the fusion and entry of the HIV-1 to the host cell [12]. In the present study, the peptide and its fluorescent 




preparative purification.  
3.2. Characterization of NPs 	
The aim of the study was to examine whether NPs could cross the first defense barrier on the surface of 
the mucosa and reach the epithelium without harming the epithelial lining. Our work also involved 
preparing PLGA NPs covered with glycol chitosan (GC) to entrap an HIV-1 inhibitor peptide and then 
release it into the vaginal mucosa of the swine. Chitosan is a natural polysaccharide composed of D-
glucosamine and N-acetyl D-glucosamine units. GC is the chitosan conjugated with ethylene glycol, it is 
water soluble below pH 5.0 and, at the same time, it retains its positive charge at physiological pH values 
[35]. The properties of the NPs obtained are summarized in Table 1. The formulation shows an average 
size (Zav) of roughly 304 nm, PI values of 0.180; ζ of 30.6 mV ± 4.2 and suitable entrapment efficiency. 
Previous studies have reported that NPs with diameters around 200-500 nm can permeate faster through 
the vaginal mucus [16]. Therefore, the presence of chitosan may increase the mucoadhesiveness of NPs 
and the retention time at the administration site, providing them with a positive superficial charge. In 
addition, chitosan has been associated with the improvement of peptide transport across the epithelial 
barrier [36].  
Table 1. Physicochemical properties and EE of NPsE2 and NPsE2-FAM	
Formulations	 Zav ± SD (nm)	 PI ± DS	 ζ ± SD (mV)	 EE ± SD (%)	
NPsE2 (a)	 305.30 ± 3.13	 0.180 ± 0.014	 30.6 ± 0.35	 62.01 ± 1.89	
NPsE2-FAM (a)	 326.10 ± 6.99	 0.210 ± 0.007	 32.5 ± 1.31	 66.67 ± 2.81	
Notes: Values are average of three independent batches, and are expressed as mean SD	
Abbreviations: Zav, average size; EE, entrapment efficiency; NPs, Nanoparticles; PI, polydispersity index; 
ζ , Zeta potential and SD, standard deviation	
 

















27.5 – 220.0	 6141	 -14418	 1	 6.8 ± 4.3	 20.6 ± 11.73	 100.17 ± 0.84	 ± 4.8	
(a). The accuracy is expressed as overall recovery percentage (n=5).	
(b)Precision intraday was obtained by back-calculated concentration for each calibration curve (n=5). 	
Acceptance criterion± 10 %	
	
3.2.1. Amino acid analysis 
Chromatograms corresponding to amino acids from the NPsE2, obtained after acid hydrolysis, are shown 
in Figure 1. The amino acids content of the analyzed NPsE2 suspension are reported in Table 3. 




together as Asp/Asn and Glu/Gln.  Tryptophan was destroyed during HCl hydrolysis. Proline, glycine and 
valine were the most abundant amino acids in the sample. The amino acid content in the sample was 
0.055 mM (109 µ/mL), which corresponding to 66.65% of total peptide added to NPs.  This result is 
























Peak name RT Area % Area Height Amount 
Asp 21.656 164441 12983 12983 0.095 
Ser 22.779 10477 914 914 0.005 
Glu 24.018 85951 7155 7155 0.051 
Gly 24.767 171911 12043 12043 0.100 
Hys 25.267     
NH4+ 26.140 11490029 67.85 888515  
Thr 26.883 14995 0.09 3306 0.007 
Arg 27.160 11346 0.07 1389 0.006 
 28.017 14242 0.08 1565  
Ala 28.132 190431 1.12 23484 0.094 
 28.992 10982 0.06 1370  
Pro 29.331 297451 1.76 35863 0.159 
 29.800 44513 0.26 5303  
Aaba 30.611 115525 0.68 14325 0.071 
 31.465 18048 0.11 1408  
Cys 32.006 96253 0.57 8884 0.064 
Tyr 32.540     
Val 33.468 238993 1.41 27570 0.128 
Met 34.028     
 35.201 13795 0.08 820  
 35.613 18033 0.11 1202  
Lys 36.073 10921 0.06 1022 0.004 
Ile 37.438 14404 0.09 1126 0.007 
Ileu 38.092 77026 0.45 6921 0.040 
Nle 38.967     
Phe 39.830 72397 0.43 5486 0.042 
Trp 41.604     




Table 3. Amino acids contents in the NPsE2 suspension analysed 
 Amino acids nmol Theoretical Report 
2 Asp/Asn 1.668 2 1.61 
3 Thr 0.052 0 0.05 
5 Glu/Gln 0.983 1 *   0.95 
6 Pro 3.375 3 *   3.25 
7 Gly 2.172 2 *   2.09 
8 Ala 2.172 2 *   2.09 
9 Cys 1.371 3 1.32 
10 Val 2.767 3 *   2.67 
11 Met 0.065 0 0.06 
12 Ile 0.091 0 0.09 
13 Leu 0.944 1 *   0.91 
14 Tyr 0.065 0 0.06 
15 Phe 1.073 1 *   1.03 
16 His 0.181 0 0.17 
17 Lys 0.078 0 0.08 
19 Arg 0.168 0 0.16 
The amino acids that were used for calculations are those marked an asterisk (*). 
 
3.2.2.  Release in vitro  
Figure 2 shows a bi-phasic release profile of E2, characterized by an induction phase (phase I), followed 
by a sustained phase (phase II). The asymptote was reached at 5 hours, maintaining a lag-phase up to 10 
hours. The release studies were performed for 24 hours, but after 10 hours, the peptide detection was 
imprecise. This finding was attributed to peptide aggregation in the medium and adsorptive problems. 
Thus, DTT was added in the release medium to prevent the aggregation, and the time of the assays was 
also limited to10 hours. During this period, the peptide was easier to detect by HPLC/MS-MS. Although 
not all the peptide incorporated into NPs was released, the results were fitted to the Boltzmann sigmoidal 
model. Table 4 shows the model and the corresponding dissolution parameters for statistical analysis of 
E2 released from NPs. 
 A recent study reported that E2 release from liposomes was slower in buffer (PBS) than in a culture 
medium supplemented with 10% fetal bovine serum DMEM/FBS[27]. Although the release mechanisms 
of polymer systems are different from those of liposomes, similar results were obtained in the present 
study: approximately 10% of the peptide encapsulated in NPs was released in the PBS receptor medium. 
This suggests that the E2 release profile was slowed down, either as a result of a dense polymer with low 





















Figure 2. Cumulative in vitro release profile of E2 entrapped in PLGA NPs covered with GC. Data 
shown are average values from experiments performed in triplicate	
 









NPsE2	 -3.15 ± 5.64	 82.60 ± 6.87	 254.600 ± 18.40	 63.64 ± 19.15	 0.989	
 
3.3. Evaluation ex vivo the penetration of NPsE2-FAM and the amount of the E2 retained	
To evaluate the transit of the NPs loaded with E2-FAM to the vaginal epithelium, assays with 
cryopreserved mucosae were conducted ex vivo using the Franz Cells systems. To our knowledge, no 
study has reported that NPsE2 penetrates vaginal mucosa. However, some authors have described the use 
of NPs as carriers of antiretroviral drugs. For example, Das Neves and co-workers [16], reported that 
polymeric NPs measuring about 200 nm loaded with Dapivirine penetrated the excised vaginal mucosa of 
swine. In the present study, the NPsE2-FAM of 300 nm also penetrated the vaginal mucosa. The NPsE2-
FAM penetration was evaluated by confocal microscopy and the images show a fluorescent signal at the 
upper-layer of the epithelium attributed to the NPsE2-FAM (Figure 3a). These observations suggest that 
the adhesion of the NPsE2-FAM to the epithelium is due to the mucoadhesivity and bioadherence 
features associated with such systems. Some fluorescent aggregates were also found in the deep zones of 
the mucosa. The peptide released from NPs and/or NPsE2-FAM may pass through the epithelium by 
passive diffusion. Lipophilic molecules, such as E2, may cross the epithelial cell layers by the 
intercellular route or diffusion. The intercellular route may pass through the lipid bilayers or along the 




would hinder the entry of HIV-1 to the intercellular space, thus preventing fusion of the virus to target 
cells. 
Besides assessing the NPsE2-FAM penetration, the amount (Qr), of E2 retained was also measured, and 
found to be 26.66 ± 7.23 ng/g·cm-2 (n=3), p<0.05. The E2 permeation flux through the vaginal tissue was 
not calculated, as it was only detected after 5 hours of the experiment. The amount of E2 permeated at 5 
hours was 2.07 ± 0.65 ng/cm2 (n=3), p<0.05. The amount of E2 permeating through the swine’s vagina 
was lower than that retained in the tissue. This pattern might be repeated within the human mucosa. If the 
peptide levels in the mucosa were higher than the E2 systemic levels, the chances of blocking the HIV 
fusion to target-cells would increase and the viral resistance would decrease, which would reduce the 
adverse effects. The results suggest that diffusion and retention of the NPs/peptide may be influenced by 
its size and by the pathway through which the peptide crosses the mucosa. 
 

















1 - 100	 1149	 4147	 0.9984	 1.93 ± 0.96	 5.86 ± 2.92	 ± 9.6	 ± 8.87	
(a)Accuracy was evaluated by calculating residual values from linear regression of four calibration curves 
(n=4).	
(b)Precision intraday was obtained by back calculated concentration for each calibration curve (n=4). 
Acceptance criterion±10 %	
	
3.4. Evaluation in vivo of penetration of the NPsE2-FAM 	
	
In contrast to other studies in vivo, in which mice were used to examine the transit of nanoparticles across 
the vaginal mucosa [37], our we studied swine vaginal mucosa, which is considered to be similar to 
human tissue [38]. In addition, both consist of a stratified squamous epithelium supported by connective 
tissue and of the lamina propria, and they have a similar lipid composition, which is an important aspect 
of the defense barrier [39].	
The NPsE2-FAM were instilled along vaginal area. At 2 hours and 5 hours post-treatment the animals 
were sacrificed by anesthesia overdose and the vaginas were extracted. At 2 hours post-treatment, the 
fluorescent signal was distributed over the surface vaginal epithelial layer (Fig.3 b and c). This indicates 
that the NPs migrate across the mucus reaching the epithelium and spreading within the adjacent 
epithelial layers. However, at 5 hours post-treatment, the penetration profile had changed. The 
fluorescence signal was distributed only in the first epithelial layer (plane cells) with lowest signal 
intensity. At 5 hours, the NPs/Peptide may have diffused through the tissue. If peptide is released, it may 
penetrate the mucosa through lipid bilayers and interact with cellular membranes, increasing their 
concentration near the fusion sites within intercellular space. In the absence of the virus, the peptide 
might be degraded by enzymes present in the mucosa or removed by systemic withdrawal. Furthermore, 




implies that some cells may take up the NPs/peptide.  Future studies will examine this hypothesis.  
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Figure 3. Confocal images of the vaginal epithelium of swine were acquired after treatment with NPsE2-
FAM (transverse slices). The NPsE2-FAM were localized at the upper-layer of the vaginal epithelium 
(green). The nuclei were stained with DRAQ5 (blue). Fluorescence images (left column) and their 
respective differential interference contrast (DIC) images (right column) were acquired at 63X. (a) Ex 







3.5 Toxicity after application of the NPsE2-FAM in vivo	
Several methods have been used to explore the safety of anti-HIV microbicides.	Many of them are cell-
based assays in vitro; these establish the cytotoxic concentration of the drug, CC50, which is the 
concentration that reduces cell viability by 50 %, and the maximum effective concentration, EC50, which 
is the concentration that gives half-maximal response. These are essential parameters when developing 
formulations with suitable doses. However, these assays do not allow us to assess the tissue damage, such 
as the detachment of the epithelium as a result of drug-induced toxicity or the inflammatory effects of 
prolonged exposure. Histologic analyses are widely used to evaluate the toxicity after vaginal application 
of microbicides. The loss of the structure and the presence of inflammatory infiltrates in the lamina 
propria have been considered an important cytotoxicity issue related to sustained exposure to drugs 
[40,41].	
To determine harm, inflammation or epithelial upper-layer detachment, caused by NPsE2 or its 
degradation products, several slices of mucosa were cut and evaluated by microscopy. The number of 
epithelial layers in untreated mucosae was compared with the number of epithelial layers in the mucosa 
treated with NPsE2.  In all the slices observed, the number of epithelial layers post-administration was the 
same as the number of epithelial layers on the untreated mucosa (n=10). There was no evidence of 
histophatological abnormality; leukocyte infiltration to the lamina propria or epithelial lesions related to 
the treatment with NPsE2-FAM. Figure 4 (a to c) shows a conserved mucosa with a multi-layer 
epithelium followed by connective tissue. This parameter is an indication of the safety of the NPs 





















































Figure 4. Histopathological images were acquired at 100X, (left column) and 10X (right column), 
(transverse slices). (a) Vaginal epithelium not exposed to NPsE2-FAM (control), (b) Vaginal epithelium 










We present novel polymeric NPs covered with glycol-chitosan, which were successfully used to 
incorporate an HIV-1 inhibitor peptide, derived from GB virus C. NPsE2 has interesting physicochemical 
and morphological features that provide it with mobility across the mucus, to reach the vaginal epithelium 
and release the peptide.  Besides, the localization of the NPsE2-FAM at the upper-layers of the epithelial 
mucosa was considered a key aspect, since the peptide may be released at the site where HIV 
transmission occurs. Overall data indicate that NPsE2 is an interesting approached for the development of 
putative anti-HIV microbicides 
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1. Peptides characterization (E2 and E2-FAM) 
E2 and E2-FAM were analyzed by ES-MS. E2 and E2-FAM have a MW of 2166 and 2522.6 
respectively. Figures 1(a) and 2(a) shows a full scan of E2 and E2-FAM respectively, Figure 1(b) shows 
the ion products of E2 and Figure 2(b) shows UPLC chromatogram of E2-FAM  
2. Mass spectrometry and chromatographic conditions for the HIV inhibitor peptide (E2) 	
2.1. HPLC UV-VIS	
The HPLC system consisted of a Waters® 515 HPLC Pump, a 717 Plus auto sampler and a 2487 
absorbance detector dual (Waters, Milford, MA, USA). The analytical column was Kromasil 100 C18 
column (250mm×4.6mm, 5µm, Teknokroma). The peptide was detected at a wavelength of 280 nm with 
a flow rate of 1.0 mL/min. The mobile phase was acetonitrile–water (95:5 v/v) and it was chosen as it 
gave the best peak resolution. The injection volume was 25 µL. All determinations were performed at 
room temperature and isocratic conditions of elution. The retention time for the samples was 15.9 min.  
2.2. HPLC-MS/MS	
Both the peptides and their fluorescent derivatives were analyzed by ES-MS with a liquid chromatograph-
time of flight (LC-TOF). LCT Premier XE (Micromass Waters (Mildford, MA, USA), coupled to 
Analytical Ultra Performance Liquid Chromatography apparatus (UPLC, Waters, Mildford, MA, USA). 
Samples were dissolved in a mixture of acetonitrile/water (1/1, v/v) and analyzed in the UPLC at a flow 
rate of 0.3 ml/min. LC-MS/MS was carried out on a QTrap 6500 (Absciex) mass spectrometer integrated 
on an Agilent 12690 HPLC system. The column Kinetex 2.6 µm, C18 100Å 50 x 2,1 mm column was 
used as stationary phase. The column temperature was set at 60ºC. The mobile phase consisted of a 
binary solvent system using water acidified with 0.1% formic acid (solvent A) and 100% acetonitrile 
(solvent B), kept at a flow rate of 750 µL/min. The gradient program started with 98% of eluent A and 
2% of eluent B. Eluent B rose linearly to 98% in 3 min, maintaining this level for 0.6 min. At minute 5, 
the gradient returned to the initial conditions and the column was re-equilibrated for 3 min between 
injections. The mass spectrometer was calibrated so that mass accuracy specifications and sensitivity 
were obtained over the entire mass range. Before validation and quantification, the system was optimized 
to give the highest sensitivity in the detection of peptides: peptide-standards and samples, with the most 
suitable decluttering potential (DP) and energy collision (EC) for each peptide. All the analyses used the 
turbo ion-spray source in positive mode with the following settings: ion spray voltage 5500V, DP 
(decluttering potential 171.23, entrance potential (EP) 5.00; data were recorded in multiple reaction 
monitoring mode. Transitions of 1083.0/995.5 (quantization) and 1083.0/792.8 (confirmation) were 




E2 peptide was at 2.2 minutes. Figure 3 shows a chromatogram obtained from peptide released from NPs.	
 
3. Analytical Method Validation 	
3.1 Sample Preparation 	
Stock solutions (0.22 mg/mL) of E2 were prepared in solution solvent (ACN: Milli Q Water and 1mM 
DTT (60:40 v/v). Secondary standard solutions were prepared in the matrix, (supernatant obtained of 
blank nanoparticles and solution solvent) at concentrations of 27.5; 45; 55; 90; 110; 180 and 220 µg/mL 
for HPLC UV-VIS. Likewise, the secondary standard solutions for HPLC/MS-MS were prepared in 
receptor medium used as matrix, at concentrations of 1, 3, 12, 25, 50 and 100 ng/mL. 	
Validation of the developed method was carried out as per the International Conference on 
Harmonization guidelines (ICH) (1). Characteristics such as linearity, selectivity and sensibility were 
included. 	
3.2. Linearity and Range 	
The linearity was evaluated using five calibration curves in the range from 27.5 to 220 µg /mL on the E2 
quantification by HPLC with UV detector. Four calibrated curves in the range from 1 - 100 ng/mL for 
quantification of E2 released from nanoparticles, using HPLC-MS/MS procedure. The calibration curves 
were validated interday, developed by plotting the instrument measurements versus the corresponding 
peptide concentrations. The method of least squares fit was used to statistically evaluate the results for 
linearity through a regression line and the corresponding slope, y-intercept and determination coefficients 
(r2). The regression equation was calculated: y = bx + a, where x is the concentration, (y) area of the 
chromatographic peaks, (b) is the value of the slope and a y-intercept. Furthermore, for HPLC UV-Vis 
the linearity was determined with one-way analysis of variance (ANOVA), test comparing the peak areas 
ratio versus the concentration of each standard. In addition, a run test was used, to determine whether 
HPLC-MS/MS was a linear method and whether results differ significantly from a straight line. 
Differences were considered statistically significant when p<0.05, regression analysis and mathematical 
determinations were performed by the Prism, V. 3.00 software (GraphPad Software Inc., San Diego, CA, 
USA). 	
3.3. Precision and Accuracy	
Five calibration curves were used for precision and accuracy studies and seven concentration levels were 
evaluated for each curve 
The precision expresses degree of scatter between a series of measurements. Precision was evaluated and 
expressed as the mean coefficient of variation (CV%). 
The accuracy of the analytical method expresses the closeness between experimental results and the real 
results of the sample. Accuracy was obtained calculating the percentage deviation (%EE) of the 




standard, and it is reported as percentage recovery. The method was considered precise and accurate, 




Sensitivity was calculated based on the residual standard deviation (RSD) of the response and the slope. 
Average values of five calibration curves were used for this purpose. LOD and LOQ was calculated using 
the following equations, respectively. 
 
LOD = 3.3 (SD/Slope)         (1)  
LOQ = 10 (SD/Slope)         (2) 
The slope (S) was estimated from the calibration curve. The standard deviation (SD) was calculated of the 
y-intercepts of the regression lines. Typical signal-to-noise ratio is 3.3 for LOD and 10 for LOQ.  
3.5. Applicability of Methods 	
The proposed methods were applied to quantify the E2 peptide encapsulated into PLGA nanoparticles and 
released in vaginal tissues.  The validation of these two methods will be used in upcoming studies for 





















































































Full scan  300 – 2500 

























































































TR: 2.23 min 
